HeartFlow (HTFL) Reports Strong Q3 Beat as Revenue Climbs 57%

Key Takeaways

• HeartFlow reported third-quarter 2026 revenue of $72.9 million, up 57.4% year over year and well above the consensus estimate of $65.2 million.
• Non-GAAP (adjusted) earnings per share came in at a loss of $0.03, beating consensus expectations of a $0.10 loss by $0.07.
• Non-GAAP gross margin reached 83.8%, while U.S. revenue grew 60% — the company's fastest domestic growth in 11 quarters.
• Management raised full-year 2026 revenue guidance to $262 million–$264 million, implying roughly 49%–50% year-over-year growth.
• Plaque Analysis revenue guidance was lifted to $36 million–$37 million, with about 1,300 plaque-activated accounts expected by year-end.
• Despite the top-and-bottom-line beat, shares slipped after hours, signaling that some investors had already priced in strong momentum.
• For more detail on HTFL's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Explore Trending AI Robots to discover AI-driven trading ideas and strategies across the market.

Earnings Context and Why It Matters

HeartFlow is a commercial-stage medical technology company whose AI-powered platform builds personalized 3D models of a patient's heart from a single coronary computed tomography angiography (CCTA) scan, helping clinicians diagnose and manage coronary artery disease (CAD). Because the company is still scaling toward profitability, investors watch its quarterly results closely for evidence of accelerating adoption, improving gross margins, and a shrinking cash burn. The third quarter marked a third consecutive period of accelerating revenue growth, reinforcing the company's thesis that its non-invasive diagnostic tools are gaining traction with hospitals and cardiology practices. For shareholders, this report was a key test of whether HeartFlow could sustain its momentum while progressing toward its stated path to profitability.

Reported Results

For the third quarter ended September 30, 2026, HeartFlow reported total revenue of $72.9 million, a 57.4% increase from $46.3 million in the prior-year period. The result exceeded the consensus estimate of $65.2 million by roughly $7.7 million. Non-GAAP earnings per share came in at a loss of $0.03, beating analyst expectations of a $0.10 loss by $0.07. On a GAAP (Generally Accepted Accounting Principles) basis, the company posted a net loss of $11.5 million, a sharp improvement from the $50.9 million loss recorded a year earlier, which included a sizable non-cash charge.

Profitability metrics also strengthened. Non-GAAP gross margin improved to 83.8%, up from 76.8% a year ago, reflecting a richer mix of high-margin Plaque Analysis revenue, volume leverage, and ongoing artificial intelligence efficiencies. Management highlighted that U.S. revenue grew 60%, its fastest pace in 11 quarters. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Reaction and Investor Sentiment

HeartFlow's shares slipped in after-hours trading despite the clear beat on both revenue and earnings per share, suggesting that much of the positive momentum had already been reflected in the stock's valuation following a strong run over the prior months. The muted post-earnings move highlights a common dynamic for high-growth companies: beating estimates is no longer enough when investors have already priced in accelerating growth. The raised full-year guidance — now at $262 million–$264 million, up from the prior range of $246 million–$250 million — was viewed constructively, but the after-hours drift indicates a degree of profit-taking and elevated expectations heading into the print. Investors are also weighing the company's continued GAAP losses against its improving operating efficiency and expanding gross margin.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most important signal will be whether HeartFlow can sustain its revenue acceleration while continuing to close the gap toward profitability. Management's raised guidance implies roughly 49%–50% full-year revenue growth, and its confidence in reaching a midterm non-GAAP gross margin target of 85% will be closely watched.

Investors should monitor the continued adoption of the Plaque Analysis product line, which is now expected to contribute $36 million–$37 million in full-year revenue, as well as progress toward roughly 1,300 plaque-activated accounts by year-end. The company's ability to expand its footprint among hospitals and integrated health networks — particularly in the United States, where growth is fastest — remains a key demand indicator.

On the cost side, watch how operating expenses trend relative to revenue as the business scales. While the company has signaled a path to cash-flow profitability by mid-2028, ongoing investment in commercial expansion, innovation, and clinical initiatives will influence how quickly losses narrow. Reimbursement dynamics and broader healthcare spending conditions also remain relevant external factors for a diagnostic platform dependent on adoption by healthcare providers. From what I see, tracking these elements with tools like Tickeron’s AI Trend Prediction Engine can add useful perspective on potential momentum shifts.

Using AI Tools in My Research Process

In my own analysis, I frequently rely on Tickeron’s AI Screener to filter opportunities across the healthcare sector and compare technical and fundamental signals side by side. It helps surface relevant patterns and peer comparisons quickly, which is especially useful when evaluating names like HTFL that are still building scale. The tool’s customizable filters let me focus on growth metrics and industry trends without spending hours on manual review, giving a clearer view of how individual stocks fit into broader market movements.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume